[1] 王胤奎, 李子禹, 陕飞, 等. 我国早期胃癌的诊治现状——来自中国胃肠肿瘤外科联盟数据的启示[J]. 中华胃肠外科杂志,2018,21(2):168-174.
[2] Cunningham D, Allum WH, Stenning SP, et al.Periope-rative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med,2006,355(1):11-20.
[3] Bang YJ, Kim YW, Yang HK, et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, rando-mized controlled trial[J]. Lancet,2012,379(9813):315-321.
[4] Sakuramoto S, Sasako M, Yamaguchi T, et al.Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med,2007,357(18):1810-1820.
[5] Schuhmacher C, Gretschel S, Lordick F, et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40 954[J]. J Clin Oncol,2010,28(35):5210-5218.
[6] Ychou M, Boige V, Pignon JP, et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol,2011, 29(13):1715-1721.
[7] NCCN. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer[EB/OL]. Version 2.2018. (2018-05-22)[2018-12-03]. http://www.nccn.org.
[8] Edge SB, Byrd DR, Compton CC, et al.AJCC Cancer Staging Manual[M]. 7 ed. New York:Springer,2010.
[9] Amin MB, Edge SB, Greene FL, et al.AJCC Cancer Staging Manual[M]. 8 ed. New York:Springer,2017.
[10] Greene FL, Page DL, Fleming ID.AJCC Cancer Staging Manual[M]. 6 ed. New York:Springer,2002.
[11] Valentini V, Cellini F, Minsky BD, et al.Survival after radiotherapy in gastric cancer: systematic review and meta-analysis[J]. Radiother Oncol,2009,92(2):176-183.
[12] van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med,2012,366(22):2074-2084.
[13] Stahl M, Walz MK, Stuschke M, et al.Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol,2009,27(6):851-856.
[14] Leong T, Smithers BM, Michael M, et al.TOPGEAR: a randomised phase Ⅲ trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)[J]. BMC Cancer,2015,15:532.
[15] Burmeister BH, Thomas JM, Burmeister EA, et al.Is concurrent radiation therapy required in patients recei-ving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase Ⅱ trial[J]. Eur J Cancer,2011,47(3):354-360.
[16] Persiani R, D'Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer(LAGC) treated with preoperative chemotherapy and D2-gastrectomy[J]. J Surg Oncol,2005,89(4):227-238.
[17] D'Ugo D, Persiani R, Rausei S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer[J]. Eur J Surg Oncol,2006,32(10):1105-1109.
[18] Spigel DR, Greco FA, Meluch AA, et al.Phase Ⅰ/Ⅱ trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in loca-lized carcinoma of the esophagus or gastroesophageal junction[J]. J Clin Oncol,2010,28(13):2213-2219.
[19] Ajani JA, Mansfield PF, Janjan N, et al.Multi-institu-tional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma[J]. J Clin Oncol,2004,22(14):2774-2780.
[20] Lowy AM, Feig BW, Janjan N, et al.A pilot study of preoperative chemoradiotherapy for resectable gastric cancer[J]. Ann Surg Oncol,2001,8(6):519-524.
[21] Ajani JA, Walsh G, Komaki R, et al.Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction[J]. Cancer,2004,100(11):2347-2354.
[22] Ajani JA, Mansfield PF, Crane CH, et al.Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome[J]. J Clin Oncol,2005,23(6):1237-1244.
[23] Ajani JA, Winter K, Okawara GS, et al.Phase Ⅱ trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response[J]. J Clin Oncol,2006,24(24):3953-3958.
[24] Wydmanski J, Suwinski R, Poltorak S, et al.The tole-rance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase Ⅱ study[J]. Radiother Oncol,2007,82(2):132-136.
[25] Reed VK, Krishnan S, Mansfield PF, et al.Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys,2008,71(3):741-747.
[26] Rivera F, Galan M, Tabernero J, et al.Phase Ⅱ trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma[J]. Int J Radiat Oncol Biol Phys,2009,75(5):1430-1436.
[27] Díaz-González JA, Rodríguez J, Hernández-Lizoain JL, et al.Patterns of response after preoperative treatment in gastric cancer[J]. Int J Radiat Oncol Biol Phys,2011,80(3):698-704.
[28] Pera M, Gallego R, Montagut C, et al.Phase Ⅱ trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer[J]. Ann Oncol,2012,23(3):664-670.
[29] Valenti V, Hernandez-Lizoaín JL, Beorlegui MC, et al.Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy[J]. J Surg Oncol,2011,104(2):124-129.
[30] Stahl M, Walz MK, Riera-Knorrenschild J, et al.Preope-rative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial[J]. Eur J Cancer,2017,81:183-190.
[31] Zhang ZX, Gu XZ, Yin WB, et al.Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients[J]. Int J Radiat Oncol Biol Phys,1998,42(5):929-934.
[32] Leong T, Smithers BM, Haustermans K, et al.TOPGEAR: a randomized, phase Ⅲ trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG[J]. Ann Surg Oncol,2017,24(8):2252-2258.
[33] Macdonald JS, Smalley SR, Benedetti J, et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J]. N Engl J Med,2001,345(10):725-730.
[34] Lee J, Lim DH, Kim S, et al.Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol,2012,30(3):268-273.
[35] Park SH, Sohn TS, Lee J, et al.Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses[J]. J Clin Oncol,2015,33(28):3130-3136.
[36] Cheedella NK, Suzuki A, Xiao L, et al.Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort[J]. Ann Oncol,2013,24(5):1262-1266.
[37] Al-Batran SE, Hofheinz RD, Pauligk C, et al.Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial[J]. Lancet Oncol,2016,17(12):1697-1708.
[38] Al-Batran S, Homann N, Schmalenberg H, et al.Perio-perative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial[J]. J Clin Oncol,2017,35(15suppl):4004.
[39] NCI. A phase Ⅲ trial evaluating the addition of trastuzumab to trimodality treatment of HER2-overexpressing esophageal adenocarcinoma[EB/OL].2010. [2018-12-03]. https://clinicaltrials.gov/ct2/show/NCT01196390.
[40] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature,2014,513(7517):202-209.
